CA2327584A1 - Virus attenue de la grippe - Google Patents
Virus attenue de la grippe Download PDFInfo
- Publication number
- CA2327584A1 CA2327584A1 CA002327584A CA2327584A CA2327584A1 CA 2327584 A1 CA2327584 A1 CA 2327584A1 CA 002327584 A CA002327584 A CA 002327584A CA 2327584 A CA2327584 A CA 2327584A CA 2327584 A1 CA2327584 A1 CA 2327584A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- influenza
- cells
- segment
- viruses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16041—Use of virus, viral particle or viral elements as a vector
- C12N2760/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne un virus atténué de la grippe portant un segment d'acide nucléique génomique qui comprend des régions 5' et 3' non codantes constituant une région double mutée d'un segment génomique d'ARN de virus de la grippe, liée de manière opérationnelle à une séquence codant pour une protéine d'une protéine virale de la grippe, ou une modification fonctionnelle de celui-ci. Ladite région double comporte au moins une substitution de paire de bases telle que l'expression de ladite séquence codant pour une protéine dans des cellules infectées par ledit virus est réduite de manière à former un phénotype atténué. Le virus atténué de la grippe peut être utilisé dans un vaccin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9809666.2 | 1998-05-06 | ||
GBGB9809666.2A GB9809666D0 (en) | 1998-05-06 | 1998-05-06 | Modified viruses |
PCT/GB1999/001413 WO1999057284A2 (fr) | 1998-05-06 | 1999-05-06 | Virus attenue de la grippe |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2327584A1 true CA2327584A1 (fr) | 1999-11-11 |
Family
ID=10831535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002327584A Abandoned CA2327584A1 (fr) | 1998-05-06 | 1999-05-06 | Virus attenue de la grippe |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1075524A2 (fr) |
JP (1) | JP2002513575A (fr) |
AU (1) | AU3723099A (fr) |
CA (1) | CA2327584A1 (fr) |
GB (1) | GB9809666D0 (fr) |
WO (1) | WO1999057284A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7465574B2 (en) | 1994-09-30 | 2008-12-16 | Medimmune, Llc | Recombinant RSV virus expression systems and vaccines |
US6830748B1 (en) | 1997-09-26 | 2004-12-14 | Medimmune Vaccines, Inc. | Recombinant RSV virus expression systems and vaccines |
US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
NO346351B1 (no) * | 2005-10-19 | 2022-06-20 | Intervet Int Bv | Isolert hundedyr influensa Avirus, polynukleotid-ekspresjonskonstruksjon, isolert antistoff, isolert celle, reassortant virus og rekombinant virusvektor, samt sammensetning og hundeinfluensavaksine |
WO2010144797A2 (fr) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations |
KR20130048208A (ko) | 2010-03-11 | 2013-05-09 | 이뮨 디자인 코포레이션 | 인플루엔자 백신 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0704533A1 (fr) * | 1994-09-30 | 1996-04-03 | Bayer Ag | Virus atténué pour la vaccination, méthode pour sa fabrication et compositions pharmaceutiques le contenant |
-
1998
- 1998-05-06 GB GBGB9809666.2A patent/GB9809666D0/en not_active Ceased
-
1999
- 1999-05-06 AU AU37230/99A patent/AU3723099A/en not_active Abandoned
- 1999-05-06 WO PCT/GB1999/001413 patent/WO1999057284A2/fr not_active Application Discontinuation
- 1999-05-06 EP EP99919444A patent/EP1075524A2/fr not_active Withdrawn
- 1999-05-06 CA CA002327584A patent/CA2327584A1/fr not_active Abandoned
- 1999-05-06 JP JP2000547239A patent/JP2002513575A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1075524A2 (fr) | 2001-02-14 |
JP2002513575A (ja) | 2002-05-14 |
AU3723099A (en) | 1999-11-23 |
WO1999057284A2 (fr) | 1999-11-11 |
GB9809666D0 (en) | 1998-07-01 |
WO1999057284A3 (fr) | 1999-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7384774B2 (en) | Helper-free rescue of recombinant negative strand RNA virus | |
Subbarao et al. | Rescue of an influenza A virus wild-type PB2 gene and a mutant derivative bearing a site-specific temperature-sensitive and attenuating mutation | |
EP1697521B1 (fr) | Systeme a plasmides multiples pour la production du virus de la grippe | |
US9238825B2 (en) | Multi plasmid system for the production of influenza virus | |
US9068986B2 (en) | Influenza B viruses having alterations in the hemagglutinin polypeptide | |
EP1499348B1 (fr) | Methode pour la production de virus influenza b infectieux en culture cellulaire | |
EP1945778B1 (fr) | Procédé pour ameliorer la réplication du virus de la grippe | |
EP1748790B1 (fr) | Systeme multiplasmide pour la production d'un virus grippal | |
CA2327584A1 (fr) | Virus attenue de la grippe | |
Machado et al. | Recombinant influenza A viruses harboring optimized dicistronic NA segment with an extended native 5′ terminal sequence: induction of heterospecific B and T cell responses in mice | |
EP1200563B1 (fr) | Virus attenue de la grippe utilisable comme vaccin | |
Zhang | Expression of influenza virus a replication proteins and role of 5'-untranslated region in translational regulation | |
AU2012201931A1 (en) | Multi-plasmid system for the production of influenza virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |